Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium Tc-99m heparin is a radiopharmaceutical diagnostic agent composed of the gamma-emitting radionuclide technetium-99m (Tc-99m) complexed with heparin, a naturally occurring glycosaminoglycan. This agent is primarily utilized in nuclear medicine for the scintigraphic detection and localization of acute deep vein thrombosis (DVT) and other thromboembolic disorders. The diagnostic utility relies on the inherent affinity of heparin for fibrin and actively forming thrombi, where it binds to antithrombin III and remains localized at the site of the clot. Following intravenous administration, the Tc-99m label allows for external imaging via gamma cameras. While it has been extensively studied for thrombus imaging, it remains largely an investigational tool or a specialized diagnostic rather than a first-line clinical standard in modern radiology, often superseded by ultrasound or other radiolabeled agents like Tc-99m apcitide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on technetium Tc-99m heparin.